Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Picrasidine J, a Dimeric β-Carboline-Type Alkaloid from Picrasma quassioides , Inhibits Metastasis of Head and Neck Squamous Cell Carcinoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, Switzerland : MDPI, [2000-
    • Subject Terms:
      Picrasma* ; Alkaloids*/pharmacology ; Antineoplastic Agents*/pharmacology ; Head and Neck Neoplasms*/drug therapy; Squamous Cell Carcinoma of Head and Neck ; Carbolines ; Polymers
    • Abstract:
      Head and neck squamous cell carcinoma (HNSCC) are associated with recurrence, distant metastasis, and poor overall survival. This highlights the need for identifying potential therapeutics with minimal side-effects. The present study was designed to investigate the anticancer effects of picrasidine J, a dimeric β-carboline-type alkaloid isolated from the southern Asian plant Picrasma quassioides. The results showed that picrasidine J significantly inhibits HNSCC cell motility, migration, and invasion. Specifically, picrasidine J inhibited the EMT process by upregulating E-cadherin and ZO-1 and downregulating beta-catenin and Snail. Moreover, picrasidine J reduced the expression of the serine protease KLK-10. At the signaling level, the compound reduced the phosphorylation of ERK. All these factors collectively facilitated the inhibition of HNSCC metastasis with picrasidine J. Taken together, the study identifies picrasidine J as a potential anticancer compound of plant origin that might be used clinically to prevent the distant metastasis and progression of HNSCC.
    • References:
      Biomed Res Int. 2019 Apr 7;2019:8748253. (PMID: 31080832)
      Transl Oncol. 2020 Jun;13(6):100773. (PMID: 32334405)
      Cancer J. 2015 May-Jun;21(3):138-46. (PMID: 26049691)
      Front Cell Dev Biol. 2019 Apr 09;7:52. (PMID: 31024913)
      Arch Otolaryngol Head Neck Surg. 2006 Jun;132(6):668-77. (PMID: 16785414)
      Lancet. 2019 Nov 23;394(10212):1915-1928. (PMID: 31679945)
      J Cell Biochem. 2018 Feb;119(2):2231-2239. (PMID: 28857247)
      J Immunother Cancer. 2017 Nov 21;5(1):95. (PMID: 29162153)
      Trends Cancer. 2020 Nov;6(11):942-950. (PMID: 32680650)
      Oral Oncol. 2021 Apr;115:105168. (PMID: 33730628)
      Curr Treat Options Oncol. 2017 Jun;18(6):38. (PMID: 28550447)
      Sci China Life Sci. 2022 Oct;65(10):2031-2049. (PMID: 35366152)
      J Nat Prod. 2016 Dec 23;79(12):3127-3133. (PMID: 27958735)
      Biochem Biophys Res Commun. 2018 May 15;499(3):584-593. (PMID: 29621546)
      Breast Cancer Res. 2012 Jan 19;14(1):202. (PMID: 22264257)
      Clin Cancer Res. 2007 May 15;13(10):2905-15. (PMID: 17504990)
      Environ Toxicol. 2017 Feb;32(2):645-655. (PMID: 27037602)
      Tumour Biol. 2004 Jul-Aug;25(4):193-9. (PMID: 15557757)
      Nat Rev Cancer. 2018 May;18(5):269-282. (PMID: 29497144)
      Int J Mol Sci. 2022 Mar 31;23(7):. (PMID: 35409206)
      Environ Toxicol. 2022 Mar;37(3):627-636. (PMID: 34894061)
      Nat Rev Dis Primers. 2020 Nov 26;6(1):92. (PMID: 33243986)
      J Clin Oncol. 2013 Mar 1;31(7):845-52. (PMID: 23182993)
      Molecules. 2016 Jul 22;21(7):. (PMID: 27455225)
      Nat Rev Cancer. 2004 Nov;4(11):876-90. (PMID: 15516960)
      Environ Toxicol. 2021 Sep;36(9):1848-1856. (PMID: 34076342)
      Bioorg Med Chem Lett. 2017 Jun 1;27(11):2608-2612. (PMID: 28427809)
      Plants (Basel). 2017 Sep 22;6(4):. (PMID: 28937585)
      Int J Mol Sci. 2019 Oct 09;20(20):. (PMID: 31600949)
      Lancet Oncol. 2007 Jul;8(7):613-24. (PMID: 17543584)
      Arch Pathol Lab Med. 2015 Nov;139(11):1349-61. (PMID: 26172508)
      Ann Oncol. 2017 Jul 01;28(7):1605-1611. (PMID: 28419181)
      Oral Oncol. 2006 Mar;42(3):306-16. (PMID: 16321566)
      J Biol Chem. 2005 Apr 15;280(15):14628-35. (PMID: 15713679)
      J Nat Prod. 2016 Apr 22;79(4):879-85. (PMID: 27025413)
      Front Pharmacol. 2020 Jan 28;10:1614. (PMID: 32116665)
      Int J Mol Sci. 2022 May 29;23(11):. (PMID: 35682782)
    • Contributed Indexing:
      Keywords: EMT; KLK-10; MAPK signaling; head and neck carcinoma; metastasis; picrasidine J
    • Accession Number:
      0 (Alkaloids)
      0 (Carbolines)
      0 (Antineoplastic Agents)
      0 (Polymers)
    • Publication Date:
      Date Created: 20230909 Date Completed: 20230911 Latest Revision: 20230911
    • Publication Date:
      20250114
    • Accession Number:
      PMC10487624
    • Accession Number:
      10.3390/ijms241713230
    • Accession Number:
      37686036